AMRN vs RDY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AMRN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMRN and RDY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMRN and RDY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amarin Corporation is a pharmaceutical company whose business is dominated by one product, VASCEPA (marketed as VAZKEPA in Europe), the brand name for icosapent ethyl, a highly purified omega-3 prescription therapy derived from fish oil. VASCEPA lowers triglycerides and, based on a cardiovascular outcomes trial, is used to reduce the risk of cardiovascular events in certain statin-treated patients with elevated triglycerides. Amarin makes money by selling VASCEPA in the United States and by licensing and collecting royalties from partners who commercialize the drug in other regions. Because the company depends so heavily on a single molecule, its fortunes track VASCEPA's prescription volumes, pricing, and competitive dynamics rather than a diversified portfolio.

Full AMRN guide

Dr. Reddy's Laboratories, founded in 1984 and based in Hyderabad, India, is one of the largest Indian pharmaceutical companies, spanning active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. Its therapeutic focus areas include gastrointestinal, cardiovascular, diabetes, oncology, pain management, and dermatology, and its major markets are the United States, India, Russia and CIS, Europe, and emerging markets. The US generics arm (Dr. Reddy's Laboratories, Inc., based in Princeton, New Jersey) is the single largest revenue contributor, and the company trades on the NYSE as an American Depositary Receipt (ADR) while also listing in India.

Full RDY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMRN drivers: Stabilizing the US VASCEPA franchise; International expansion through partners.
• RDY drivers: Biosimilars ramp; GLP-1 / semaglutide opportunity.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The overriding risk is single-product concentration: Amarin's fortunes rest almost entirely on VASCEPA, so any pressure on that franchise flows straight to the company. For RDY, the loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMRN if you believe its drivers more; RDY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMRN and RDY guides.

AMRN. These figures are approximate, tied to the asOf date, and should be verified against Amarin's latest filings before acting. For a company in revenue transition, headline multiples are less meaningful than the trajectory of US branded volumes, international royalty growth, and cash generation. A large cash balance relative to market value is part of the value case, but cash can be consumed if the business does not stabilize, so watch the cash-flow trend rather than any single quarter.

RDY. FY2026 (year ended March 31, 2026) revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, but Q4 profit before tax collapsed to about 2.6% of revenue as the Revlimid exclusivity ended and margins compressed. The stock trades around a mid-20s price-to-earnings multiple with a low payout ratio (near 15%) and a modest sub-1% dividend yield. Figures are approximate, converted from Indian rupee reporting, and can shift with exchange rates and each quarterly release.

Headline figures (approximate, Jul 2026): AMRN shows total net revenue (q1 2026) ~$45 million reported, up modestly year over year per the company (verify live), revenue mix Mostly US VASCEPA product sales plus growing licensing and royalty income from international partners, profitability Operating and net losses reported in Q1 2026 but narrowing sharply as costs were cut, cash flow Company reported positive cash flow in consecutive quarters and targets full-year 2026 positive cash flow; RDY shows revenue (fy26) ~$4.0B, market cap ~$12.8B, p/e (normalized) ~27x, fy26 ebitda margin ~22.8%.

AMRN and RDY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMRN and RDY exposure against your real portfolio. It is not an investment adviser.